Multiple Approaches to Abeta Vaccination in Animal Models

动物模型中 Abeta 疫苗接种的多种方法

• 批准号: 7278237
• 负责人: David Hastings Cribbs
• 金额: $ 40.38万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7278237
• 关键词: AN-1792; Abeta clearance; Active Immunization; Active Immunotherapy; Addendum; Adjuvant; Adverse event; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease risk; Amyloid beta-Protein; Animal Model; Anti-Inflammatory Agents; Anti-inflammatory; Antibodies; Antibody Formation; Antigens; Apoptosis; Area; Astrocytes; Attention; Attenuated; Autoantigens; B-Lymphocyte Epitopes; B-Lymphocytes; Blood - brain barrier anatomy; Blood Cells; Blood Vessels; Brain; Case Study; Cells; Chimeric Proteins; Chronic; Clinical Trials; Cobra Venoms; Complement; Complement Activation; Complement Inactivators; Complex; Custom; Cutaneous; DNA; DNA Recombinant Proteins; Data; Deposition; Development; Diet; Disease; Dose; Elderly; Epitopes; Event; Fc Receptor; Funding; Gene Chips; Gene Expression; Genes; Goals; Hemorrhage; Human; Immune response; Immune system; Immunization; Immunologic Monitoring; Immunotherapy; Impaired cognition; Incidence; Individual; Inflammation; Inflammatory; Inflammatory Response; Information Systems; Interleukin-16; Link; Localized; Mediating; Memory; Meningeal; Meningoencephalitis; Microglia; Minocycline; Modeling; Molecular; Mus; Nerve Degeneration; Neuraxis; Neurodegenerative Disorders; Neuroglia; Outcome; Passive Immunization; Passive Immunotherapy; Pathology; Pathway interactions; Patients; Pattern; Peripheral; Personal Satisfaction; Phase; Physicians; Population; Predisposition; Principal Investigator; Process; Property; Proteins; Protocols documentation; QS21; Quil A; Recombinants; Reporting; Research Personnel; Risk; Risk Factors; Rodent; Role; STAT1 gene; Safety; Site; T-Lymphocyte; T-Lymphocyte Epitopes; Testing; Tg2576; Translating; Translations; Treatment Protocols; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors; Vaccination; Vaccines; Vertebral column; Week; aged; autoreactive T cell; base; central nervous system injury; cerebrovascular; cobra venom factor; cytokine; design; human TNF protein; in vivo; interest; macrophage; macrophage-derived chemokine; mouse model; novel; older patient; programs; prototype; research study; response; vaccination strategy; vaccine delivery

DESCRIPTION (provided by applicant): Abeta-immunotherapy has received considerable attention as a promising approach for reducing the level of the Abeta in the CNS of AD patients. However, the first clinical trial, AN 1792, was halted when a subset of those immunized with Abeta42 developed adverse events in the central nervous system, and data from the trial indicate that there was a low percentage of responders and generally low liters in the patients that received the vaccine. Overcoming the problems associated with inducing a safe, economical, and adequate immune response in elderly AD patients will require the development of suitable vaccine and strategies to avoid adverse events associated with immunized elderly AD patients. The goals for this proposal are to design a vaccine that is suitable for rapid translation to a clinical trial in AD patients, to identify risk factors associated with active and passive vaccination strategies using APP/Tg models, and to test neurovascular protective approaches as an addendum to immunotherapy. Accordingly, we have divided this competitive renewal application into three areas of focus (Aims) that collectively will help overcome the significant hurdles facing Abeta-immunotherapy: 1) To design and characterize the immune response to DNA and recombinant protein epitope vaccines composed of three copies of the major Abeta B cell epitope (Abeta1-11), a foreign promiscuous Th2 epitope (PADRE), and a robust Th2 molecular adjuvant, macrophage derived chemokine (MDC); 2) To investigate the differences in clearance of Abeta and susceptibility to neurovascular pathology in old (16-20 months) and very old (20-24 months) APP/Tg2576 and Tg-SwDI mice after active or passive Abeta-immunotherapy; 3) To investigate whether neurovascular protective strategies can attenuate the anti-Abeta antibody-induced microhemorrhages in APP/Tg 2576 and Tg- SwDI mice. The goals of this proposal are to develop a safe and effective vaccine for treating Alzheimer's disease. The vaccine is designed to use the patient's own immune system to clear the brain of a factor (beta-amyloid) that has been linked to the disease. Additional studies will focus on identifying risk factors associated with immunizing elderly patients and developing protective therapies to eliminate these risk factors.

描述（由申请人提供）：作为降低AD患者CNS中Abeta水平的有前景的方法，Abeta免疫疗法受到了相当大的关注。然而，第一个临床试验AN 1792，当用Abeta 42免疫的一部分人在中枢神经系统中发生不良事件时停止，并且来自试验的数据表明，接受疫苗的患者中应答者的百分比较低，并且通常较低。克服与诱导老年AD患者安全、经济和充分的免疫应答相关的问题将需要开发合适的疫苗和策略，以避免与免疫的老年AD患者相关的不良事件。该提案的目标是设计一种适合快速转化为AD患者临床试验的疫苗，使用APP/Tg模型识别与主动和被动疫苗接种策略相关的风险因素，并测试神经血管保护方法作为免疫治疗的补充。因此，我们将这一竞争性续期申请分为三个重点领域（目标），共同帮助克服Abeta免疫治疗面临的重大障碍：1）设计和表征对由主要Abeta B细胞表位的三个拷贝组成的DNA和重组蛋白表位疫苗的免疫应答（A β 1 -11）、外源混杂Th 2表位（PADRE）和稳健Th 2分子佐剂巨噬细胞衍生趋化因子（MDC）; 2）探讨老年人A β清除率和神经血管病变易感性的差异，（16-20个月）和非常老（20-24个月）的APP/Tg 2576和Tg-SwDI小鼠在主动或被动Abeta免疫治疗后的神经血管保护策略; 3）研究神经血管保护策略是否可以减弱APP/Tg 2576和Tg-SwDI小鼠中抗Abeta抗体诱导的微血管病变。该提案的目标是开发一种安全有效的治疗阿尔茨海默病的疫苗。该疫苗旨在利用患者自身的免疫系统来清除大脑中与该疾病有关的一种因子（β-淀粉样蛋白）。更多的研究将集中在确定与老年患者免疫接种相关的风险因素，并开发保护性疗法以消除这些风险因素。